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1. Introduction 
It is widely known that cancer, one leading cause of death in 
developed countries,1 may be induced by a plethora of both 
external and internal factors, including genetic mutations. 
Accordingly, a number of types of therapeutic attack has been 
investigated.2,3 One of these involves the use of cytotoxic drugs, 
which exert their effect in many cases by means of inducing cell 
apoptosis.4 A second type of therapeutic strategy against cancer 
is based on the use of compounds with vascular-targeting 
properties. These may be due to their ability to either inhibit the 
formation of new blood vessels (antiangiogenic agents) or else to 
promote the destruction of existing ones (antivascular agents).5,6 
Tumor angiogenesis is a very complex process and involves the 
tight interplay of many factors.7 One of these is a protein called 
vascular endothelial growth factor (VEGF), a key regulator of 
angiogenesis which promotes endothelial cell survival, 
proliferation and migration while increasing vascular 
permeability.8 In fact, overexpression in the production of VEGF 
has been reported to occur in various types of tumors.9 Not 
unexpectedly, VEGF has become one further key target molecule 
in cancer therapy.10,11 
A third therapeutic line follows the path of the chromosomal 
telomeres.12 Telomeres are the terminal zones of chromosomes 
and display a special structure that fulfills at least two essential 
functions: a) they must be recognized as functional domains, thus 
distinguishing them from random chromosomal breaks that 
would stimulate the onset of repair mechanisms; b) they must 
prevent these DNA ends from fusing with other DNA ends.13 To 
comply with these functions, an appropriate amount of repetitive 
DNA sequences (telomeres) must be added to the ends of the 
chromosomes. This task is fulfilled by a special type of 
ribonucleoprotein complex called telomerase, an enzyme with 
reverse transcriptase activity. The expression of this enzyme is 
restricted or absent in normal human somatic cells and so 
telomeres progressively shorten during cell lifespan.12 This 
triggers a DNA damage response which culminates in cell 
senescence or apoptosis.14 
Shortening of telomeres during cell division provides a barrier 
for tumor progression. Indeed, cancer cells have evolved the 
ability to overcome senescence by using mechanisms capable of 
maintaining telomere lengths, such as expressing telomerase, 
which enables them to divide indefinitely. This uncontrolled cell 
growth is a key feature of cancer malignancy and has been found 
to correlate with telomerase reactivation.15 For this reason, and 
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since telomerase has been detected in about 90% of all malignant 
tumors,12 drugs with ability to inhibit telomerase activity are 
potentially useful weapons in the fight against cancer, aging and 
other diseases, including some related to premature telomere 
shortening.16 
The emergence of resistances to existing drugs has led to a 
continuous need of developing new bioactive compounds that 
overcome such problems. Even though first observed in the case 
of antibiotics, resistances have been reported to therapies with 
various types of cytotoxic,17 antiangiogenic18 and antitelomerase 
agents.19 The discovery and investigation of new members of 
these compound classes therefore constitutes an important goal in 
chemistry and pharmacology. Among the new drug types, the 
combretastatin family, which belongs like the well-known 
resveratrol to the stilbene class of natural products,20 has acquired 
an outstanding status in the last years and their members have 
been found utility in various pharmacological applications.21 The 
knowledge of the chemistry, biology, and medical potential of 
this particular compound class, discovered about 30 years ago in 
the African tree Combretum caffrum, has continued to advance.22 
Preclinical and clinical developments over the last decade have 
been rapidly accelerating for drugs such as combretastatin A-4 
(1a), most particularly in the form of its phosphate prodrug 
CA4P (1b), and for combretastatin A-1 (1c) as promising cancer 
vascular-disrupting and ophthalmology drugs (Fig. 1).22,23 Indeed, 
these encouraging developments have stimulated a variety of 
efforts devoted to the synthesis and biological evaluation of 
numerous combretastatin structural modifications.24 Recent 
reports include SAR studies that provide varying levels of cancer 
cell growth inhibition.25 
 
Figure 1. Structures of some combretastatins (1a-1c) and resveratrol. 
 
2. Research purpose 
In the present paper, we are disclosing our results in the 
synthesis and biological evaluation of a number of O-alkyl 
derivatives of combretastatin A-4 1a. These are arranged in two 
series as shown in Figure 2. One includes compounds 2a-e 
having O-alkyl residues of the allyl and benzyl type. The second 
series encompasses compounds 2f-n, which contain (E)-5-
arylpent-4-enyl residues with various aryl groups. This part of the 
structure displays an arylalkene fragment which shows similarity 
to a part of the structure of antiangiogenic stilbenes of the 
resveratrol type (Fig. 1).20,26 Accordingly, it may be expected that 
these compounds could not only exhibit cytotoxicity but also 
antiangiogenic activity. Thus, we here present the results of our 
measurements of the cytotoxicities of compounds 2a-n but also 
of their ability to inhibit the production of the VEGF. Finally, 
and in order to cover all three aforementioned lines of therapeutic 
attack, we also have tested their ability to inhibit telomerase 
activity. In our belief, the observed results might be possibly 
helpful in aiding to clear the mechanisms of action of these 
compounds. 
 
Figure 2. Structures of combretastatin O-alkyl derivatives 2a-2n used in this 
study (MOM = MeOCH2). 
 
3. Chemical results 
Combretastatin A-4 1a, the starting material for all 
compounds discussed here, was prepared according to a literature 
procedure.27 Conversion into O-alkyl derivatives 2a-2n was 
performed as depicted in Scheme 1 using bromides 3a-3n 
(Scheme 2) as the alkylating reagents. Yields are given in the 
experimental part. 
 
Scheme 1. Synthesis of combretastatin O-alkyl derivatives 2a-2n. 
 
From the alkyl bromides mentioned in Scheme 1, 3a-3e are 
commercially available. Bromides 3f-3n were synthesized by 
means of ruthenium-catalyzed cross metathesis28 between the 
commercially available bromide 4 and styrene derivatives 5-13 
(Scheme 2). Yields are given in the experimental part. 
 
Scheme 2. Synthesis of alkyl bromides 3f-3n. 
 
4. Biological results 
4.1. Cytotoxicity of combretastatine derivatives 
We first carried out a measurement of the cytotoxicity of the 
synthetic combretastatin derivatives 2a-2n. To this purpose, 
MTT assays were performed using two tumoral cells, the human 
colon HT-29 and the breast adenocarcinoma MCF-7 cell lines, as 
well as one normal cell line, the human kidney embryonic cell 
line, HEK-293.29 Cytotoxicity values, expressed as the compound 
concentration (µmol/L) that causes 50% inhibition of cell growth 
(IC50), are shown in Table 1. The observed values are in the low 
to medium micromolar range, with compound 2i showing the 
lowest values, not very different of those of combretastatin A4 
for these two particular cell lines. In addition, it is worth 
mentioning that some of the synthetic compounds are much more 
toxic for tumoral cells than for normal ones, an obviously 
desirable feature. This can better appreciated with the α and β 
coefficients, obtained by dividing the IC50 values of the normal 
cell line by those of one or the other tumoral cell line (see 
footnote in the Table). The highest value of either coefficient, the 
highest the therapeutic safety margin of the compound in the 
corresponding cell line. Thus, combretastatin A4 shows high 
values of both coefficients, most particularly in the case of the 
MCF-7 cell line. This turns out also to be the case of compounds 
2f and 2i. Compounds 2m and 2n show a good selectivity only in 
the case of the HT-29 line (α > 4) whereas compounds 2b, 2h 
and 2l show a good selectivity in the specific case of the MCF-7 
line (β > 4). 
 
Table 1. Cytotoxicity of combretastatin A4 derivatives 2a-2n.a 
Compound HT-29 MCF-7 HEK-293 α
b βc 
       CoA4 4.2 ± 0.5 1 ± 0.2 25 ± 3 5.9 25 
       2a 29 ± 3 12.0 ± 0.4 43.5 ± 0.8 1.5 3.6 
       2b 161 ± 5 5.4 ± 0.4 135 ± 13 0.8 25 
       2c 39 ± 6 59 ± 2 15 ± 3 0.4 0.3 
       2d 47 ± 5 48 ± 1 64 ± 7 1.4 1.3 
       2e 108 ± 1 29 ± 1 45 ± 4 0.4 1.6 
       2f 86 ± 6 21 ± 2 >400 >4.6 >19 
       2g 25 ± 3 41 ± 3 39 ± 2 1.6 1.0 
       2h 47 ± 7 16 ± 3 88 ± 6 1.9 5.5 
       2i 9.6 ± 0.2 4.4 ± 0.8 106 ± 9 11 24.1 
       2j 59 ± 7 8 ± 3 30 ± 2 0.5 3.7 
       2k 7 ± 0.4 42 ± 7 25 ± 4 3.6 0.6 
       2l 98 ± 8 16 ± 2 115 ± 5 1.2 7.2 
       2m 18 ± 3 40 ± 5 111 ± 3 6.2 2.8 
       2n 11 ± 2 37 ± 8 55 ± 5 5.0 1.5 
aIC50 values include those of combretastatin A4 itself and are expressed as the 
compound concentration (µmol/L) that causes 50% inhibition of cell growth, 
and are the average (± s.d.) of three different measurements (described in the 
Material and Methods section). bα = IC50 (HEK-293) / IC50 (HT-29). cβ = IC50 
(HEK-293) / IC50 (MCF-7). Values of α and β have been rounded off to a 
decimal figure. The lowest IC50 values (for tumoral cells) and the highest 
values of the α and/or β coefficients (> 4) have been highlighted in italics. 
 
 
4.2. Effect of combretastatin A4 derivatives on VEGF production 
According to that discussed in the Introduction section, we 
next investigated whether combretastatin derivatives 2a-n were 
able to inhibit or at least decrease the production of the VEGF 
protein in HT-29 tumoral cells. Figure 3 shows the results of 
VEGF production obtained by means of ELISA measurements 
after treatment of HT-29 tumoral cells with combretastatin A4 
and with compounds 2a-n dissolved in DMSO, which was the 
control substance in all experiments (in all cases, concentrations 
values below IC50 were used). With the control substance, the 
observed VEGF production was standardized to 100%, the other 
values being then referred to it. Thus, compound 2g caused the 
highest degree of inhibition in the VEGF production, which 
underwent a reduction to 38% of the control value. This is an 
even stronger effect than that caused by combretastatin A4, 
where VEGF production was reduced to 47% of the control 
value. Similarly strong effects were observed in the cases of 
compounds 2b (44%) and 2i (42%). The remaining compounds 
showed less favourable values, with compound 2e being 
essentially inactive (99%). 
 
Figure 3. VEGF protein production from HT-29 cells treated with DMSO 
(control), combretastatin A4 (CoA4) and derivatives 2a-n (at least three 
measurements were performed in each case). Bars represent mean values of 
VEGF expression (in ng/mL) and error bars indicate standard errors of the 
mean. The statistical significance was evaluated using one-sample t-tests (P < 
0.001). 
 
While the results depicted in Fig. 3 point out that compounds 
2a-n cause inhibition of the VEGF production, they do not say 
anything about the precise phase of the VEGF generation process 
with which they interfere. In order to deepen into the knowledge 
of this issue, we proceeded to determine whether the compounds 
under study were able to control protein production at the 
transcriptional level. With this idea in mind, we performed a 
reverse transcriptase/polymerase chain reaction (RT-PCR) 
analysis. For this purpose, we selected six of the combretastatin 
A4 derivatives with the highest anti-VEGF activities (2b, 2g, 2i, 
2j, 2k and 2n). As shown in Figure 4, treatment of HT-29 
tumoral cells with these derivatives and with combretastatin A4 
in DMSO did in fact cause a reduction of the transcription of 
VEGF mRNA as compared with control cells (the values of these 
are standardized to 100%). The most active derivatives turned out 
to be 2b and 2k, which proved able to reduce the expression of 
the corresponding gene to less than 70% of the control value. 
These effects are thus stronger than that of combretastatin A4 
itself, which only causes a slight reduction of the transcription 
level of VEGF mRNA (91%). Interestingly, compound 2g, which 
showed the highest degree of inhibition of VEGF production 
(Fig. 3), leaved the transcription of VEGF mRNA practically 
unaltered (97%). 
Table 2 present the same results depicted in Figures 3 and 4 
for the aforementioned six compounds (2b, 2g, 2i, 2j, 2k and 2n) 
although in the form of percentages of inhibition of VEGF 
production (100 ‒ % VEGF production) and of gene expression 
(100 ‒ % gene expression): thus, the highest values correspond to 
the strongest inhibitory effect. There is a visible lack of 
parallelism between the data of protein inhibition and those of 
gene inhibition. This suggests that these combretastatin A4 
derivatives exert the control of VEGF production at a phase 
different from that of gene transcription, perhaps during the 
posttranslational stage. 
 
 
Table 2. Inhibition of VEGF protein and of gene expression 
by combretastatin A4 and some of its O-alkyl derivatives.a 
Compound % Protein inhibitionb % Gene inhibitionc 
CoA4 53  9 
2b 56 31 
2g 62   3 
2i 58 20 
2j 49 10 
2k 49 34 
2n 52 27 
aConcentrations used were below the IC50 values. bValues obtained by 
subtracting from 100 the percentages of VEGF secretion values in Fig. 
3. cValues obtained by subtracting from 100 the percentages of VEGF 
gene inhibition values in Fig. 4. 
 
 
 
Figure 4. Agarose gel profile of products resulting from RT-PCR 
amplification. The total RNA of HT-29 cells previously treated with the 
appropriate combretastatin A4 derivative was isolated, converted into cDNA, 
and amplified by PCR as described in the Materials and Methods section 
(primers used for the RT-PCR are shown in Table 3). Gene expression of 
VEGF and β-actin was quantified using the Image J program and normalized 
to that of the housekeeping gene β-actin. At least three measurements were 
performed in each case. Bars shown represent mean activations of VEGF 
gene expression and error bars indicate standard errors of the mean. The 
statistical significance was evaluated using one-sample t-tests (P < 0.001). 
 
4.3. Effect of combretastatin A4 derivatives on telomerase 
production 
We were also interested in designing compounds with the 
ability to inhibit the expression of telomerase in tumoral cells. 
The role of this important ribonucleoprotein has been referred to 
in the Introduction.12-16 Human telomerase contains an RNA 
component (hTR) that serves as a template for the addition of the 
repeat nucleotide sequences and a protein subunit (hTERT) 
which catalyzes the nucleotide polymerization process. In 
addition, there are other associated protein factors, the role of 
which has not yet been completely elucidated. Human telomerase 
is regulated during development and differentiation, mainly 
through transcriptional control of the hTERT gene, the 
expression of which is restricted to cells that exhibit telomerase 
activity. This indicates that hTERT is the rate limiting factor of 
the enzyme complex.16a For the expression of the hTERT gene, 
two transcriptional factors called c-Myc and Sp1, among others, 
have been found to play an important role through upregulation 
of the mRNA encoding the hTERT protein subunit of 
telomerase.30 Thus, and as a preliminary study of the potential 
anti-telomerase activity of combretastatin derivatives, we have 
investigated their ability to inhibit the expression of the hTERT 
and c-myc genes. 
 
 
 
Figure 5. Agarose gel profile of products resulting from RT-PCR 
amplification. The total RNA of HT-29 cells previously treated with the 
appropriate compound was isolated, converted into cDNA, and amplified by 
PCR as described in the Materials and Methods section (primers used for the 
RT-PCR are shown in Table 3). Gene expression of hTERT, c-myc and β-
actin was quantified using the Image J program and normalized to that of the 
housekeeping gene β-actin. At least three measurements were performed in 
each case. Bars shown represent mean activations of hTERT and c-myc gene 
expression and error bars indicate standard errors of the mean. The statistical 
significance was evaluated using one-sample t-tests (P < 0.001). 
 
In order to determine whether O-alkyl derivatives of 
combretastatin A4 were able to regulate the expression of the 
hTERT and c-myc genes, we have performed a RT-PCR analysis 
using HT-29 tumoral cells. For that purpose, we selected the 
same group of derivatives (2b, 2g, 2i, 2j, 2k and 2n) previously 
investigated for their antiangiogenic activity. The results, 
depicted in Figure 5, show that treatment of HT-29 cells with 
combretastatin A4 and the aforementioned derivatives dissolved 
in DMSO leads in fact to various degrees of reduction in the 
transcription of hTERT and c-myc mRNA as compared with 
control cells. The most active derivative was found to be 2n, 
which proved able to reduce the expression of both genes to less 
than 40% of the control value. For the sake of comparison, 
combretastatin A4 caused a reduction to 74% of the control value 
in the case of the hTERT gene and proved practically inactive in 
the case of the c-myc gene. 
Comparison of the results for the expression of the hTERT 
gene with those of the c-myc gene reveals a good correlation 
between them (Fig. 5). We may conclude therefore that the 
compounds under study downregulate the expression of the 
hTERT gene by lowering the transcription of the c-myc gene. 
 
5. Summary 
A series of O-alkyl derivatives of combretastatin A4 has been 
prepared and evaluated in relation to three types of biological 
properties: cytotoxicity, antiangiogenesis and telomerase 
inhibition. One healthy (human kidney embryonic, HEK-293) 
and two tumoral cell lines (human colon HT-29 and breast 
adenocarcinoma MCF-7) were used for the assays. 
No clear correlations are perceived between structure and 
activity in the compounds under study. For instance, the strongest 
cytotoxicities (lowest IC50 values) and the highest α or β values 
are found almost exclusively among the compounds containing 
the (E)-arylalkene fragment, i.e., within the 2f-2n group (Table 
1). However, the observed IC50 values do not bear a close 
relationship with the α/β coefficients. Only in the case of 
compound 2i was an appreciable cytotoxicity towards both 
tumoral cell lines accompanied by high α and β values. In other 
cases (e.g. 2f, 2h, 2n), these desirable features were observed in 
only one of the two cell lines. 
The inhibition of the VEGF production, as a measure of the 
antiangiogenic activity, did not show a very marked relation with 
the structural type, either. Except for 2c and 2e, which were 
clearly less active, all other compounds displayed comparable 
activities, with 2g being the most active. The most outstanding 
aspect here was that some of the compounds (2b, 2g and 2i) 
proved even more active in this property than combretastatin A4. 
Again, these belong to the 2f-2n group. From these, 2i also 
showed favourable cytotoxicity indexes, as commented above. 
The ability to inhibit the expression of the hTERT and c-myc 
genes was also found in the investigated combretastatin A4 
derivatives. The profile was, however, clearly different from that 
observed in the two other biological properties. For example, the 
strongest activity was found here in compound 2n, with 
compounds 2b, 2g and 2i, which had favourable antiangiogenic 
features, being much less active. Nonetheless, it is worth noting 
that several of the compounds displayed a higher activity than 
combretastatin A4. Once again, the compounds of the 2f-2n 
group were found more active than the simple O-alkyl 
derivatives. 
In summary, some of the investigated combretastatin A4 O-
alkyl derivatives show an activity comparable or higher than that 
of combretastatin A4 itself in at least one of the three examined 
biological properties. While it seems that compounds containing 
the (E)-arylalkene fragment (2f-2n) display in general stronger 
activities than the simple O-alkyl derivatives (2a-2e), no clear 
structure/activity correlations were perceived, however, when 
comparing the observed compound activities across the three 
biological properties. This points out the existence of marked 
differences between the mechanisms responsible for their 
cytotoxicity. 
 
6. Materials and Methods 
6.1. Chemistry: general procedures 
General features. NMR spectra were recorded at 500 MHz 
(1H NMR) and 125 MHz (13C NMR) in CDCl3 solution at 25 °C, 
if not otherwise indicated, with CDCl3 signals as internal 
reference. 13C NMR signal multiplicities were determined with 
the DEPT pulse sequence. Mass spectra were run in the 
electrospray (ESMS) mode. Reactions which required an inert 
atmosphere were carried out under dry N2 with flame-dried 
glassware. Commercial reagents were used as received. 
Dichloromethane was freshly distilled from CaH2. Column 
chromatography was performed on a silica gel column (60-200 
µm) with elution with the indicated solvent mixtures. 
6.2. Reaction conditions 
6.2.1. Styrene derivatives 
Styrene derivatives 5-7 and 11-13 are commercially available. 
Styrenes 8-10 were prepared as reported31 by means of Wittig 
methylenation of the appropriate commercial benzaldehydes 
(yields in the range 60-70%): 
8: oil; 1H NMR (500 MHz) δ 7.54 (1H, dd, J = 7.7, 1.5 Hz), 7.26 
(1H, td, J = 7.7, 1.5 Hz), 7.20-7.10 (2H, m), 7.04 (1H, td, J = 7.5, 
1 Hz), 5.80 (1H, dd, J = 17.7, 1.5 Hz), 5.33 (1H, dd, J = 11, 1.5 
Hz), 5.25 (2H, s), 3.53 (3H, s); 13C NMR (125 MHz) δ 154.4, 
127.6 (C), 131.5, 128.8, 126.4, 121.9, 114.8 (CH), 114.5, 94.7 
(CH2), 56.0 (CH3). 
9: oil; 1H NMR (500 MHz) δ 7.26 (1H, t, J = 7.9 Hz), 7.12 (1H, 
br t, J ∼ 2 Hz), 7.08 (1H, br d, J ∼ 7.6), 6.97 (1H, ddd, J = 7.9, 
2.4, 1 Hz), 6.71 (1H, dd, J = 17.5, 10.8 Hz), 5.77 (1H, dd, J = 
17.5, 1 Hz), 5.27 (1H, dd, J = 10.8, 1 Hz), 5.21 (2H, s), 3.51 (3H, 
s); 13C NMR (125 MHz) δ 157.6, 139.2 (C), 136.7, 129.5, 120.1, 
115.7, 114.0 (CH), 114.3, 94.5 (CH2), 56.0 (CH3). 
10: oil; 1H NMR (500 MHz) δ 7.38 (2H, br d, J ∼ 8.5 Hz), 7.05 
(2H, br d, J ∼ 8.5 Hz), 6.71 (1H, dd, J = 17.6, 11 Hz), 5.77 (1H, 
d, J = 17.6 Hz), 5.21 (2H, s), 5.20 (1H, d, J = 11 Hz), 3.52 (3H, 
s); 13C NMR (125 MHz) δ 157.0, 131.6 (C), 136.2, 127.3 (x 2), 
116.3 (x 2) (CH), 112.0, 94.4 (CH2), 55.9 (CH3). 
 
6.2.2. Synthesis of bromides 3f-3n by means of cross metathesis 
Representative example: a solution of bromide 4 (60 µL, 75 
mg, ca. 0.5 mmol) and styrene 6 (235 mg, 1.75 mmol) in dry, 
degassed CH2Cl2 (50 mL) was treated with Ru-II catalyst (150 
mg, 0.175 mmol). The reaction mixture was then stirred at reflux 
under N2 for 24 h. Subsequently, the mixture was treated with 
DMSO (600 µL)32 and stirred overnight at room temperature. 
The reaction mixture was then evaporated under reduced 
pressure, and the residue was carefully chromatographed on silica 
gel (elution with hexane-Et2O, 400:1)33. This gave 3g (55 mg, 
43% based on 4) together with the stilbene derivative generated 
by homodimerization of 6 (major product). In the other 
examples, yields were in the range 35-50% except for bromides 
3l-3n, which could not be purified and were obtained only in 
admixture with variable percentages of the homodimerization 
products. The mixtures were then used for the alkylation step. 
3f: oil; 1H NMR (500 MHz) δ 7.43 (1H, br d, J ∼ 7.8 Hz), 7.22 
(1H, br t, J ∼ 7.8 Hz), 6.94 (1H, t, J = 7.8 Hz), 6.88 (1H, br d, J ∼ 
7.8 Hz), 6.79 (1H, d, J = 16 Hz), 6.20 (1H, dt, J = 16, 7 Hz), 3.87 
(3H, s), 3.48 (2H, t, J = 7 Hz), 2.42 (2H, br q, J ∼ 7 Hz), 2.07 
(2H, br quint, J ∼ 7 Hz); 13C NMR (125 MHz) δ 156.4, 126.4 (C), 
129.2, 128.1, 126.5, 126.0, 120.6, 110.9 (CH), 33.2, 32.4, 31.8 
(CH2), 55.5 (CH3); HR EIMS m/z (rel. int.) 254.0351 (M+, 40), 
239 (M+−Me, 100). Calcd. for C12H1579BrO, 254.0306. 
3g: oil; 1H NMR (500 MHz) δ 7.23 (1H, t, J = 7.8 Hz), 6.96 (1H, 
br d, J ∼ 7.8 Hz), 6.91 (1H, br t, J ∼ 2 Hz), 6.79 (1H, dd, J = 7.8, 
2.5 Hz), 6.44 (1H, d, J = 16 Hz), 6.18 (1H, dt, J = 16, 7 Hz), 3.83 
(3H, s), 3.47 (2H, t, J = 7 Hz), 2.40 (2H, br q, J ∼ 7 Hz), 2.05 
(2H, br quint, J ∼ 7 Hz); 13C NMR (125 MHz) δ 159.8, 138.9 (C), 
131.2, 129.5, 128.8, 118.7, 112.8, 111.4 (CH), 33.1, 32.2, 31.2 
(CH2), 55.2 (CH3); HR EIMS m/z (rel. int.) 254.0336 (M+, 80), 
175 (M+−Br, 100), 147 (M+−Br−C2H4, 98). Calcd. for 
C12H1579BrO, 254.0306. 
3h: oil; 1H NMR (500 MHz) δ 7.30 (2H, br d, J ∼ 8.5 Hz), 6.86 
(2H, br d, J ∼ 8.5 Hz), 6.41 (1H, d, J = 16 Hz), 6.04 (1H, dt, J = 
16, 7 Hz), 3.82 (3H, s), 3.46 (2H, t, J = 7 Hz), 2.38 (2H, br q, J ∼ 
7 Hz), 2.05 (2H, br quint, J ∼ 7 Hz); 13C NMR (125 MHz) δ 
158.9, 128.6 (C), 130.7 (x 2), 127.1 (x 2), 126.3, 114.0 (CH), 
33.2, 32.4, 31.3 (CH2), 55.3 (CH3); HR EIMS m/z (rel. int.) 
254.0362 (M+, 45), 175 (M+−Br, 12), 147 (M+−Br−C2H4, 100). 
Calcd. for C12H1579BrO, 254.0306. 
3i: oil; 1H NMR (500 MHz) δ 7.45 (1H, br d, J ∼ 7.8 Hz), 7.19 
(1H, br t, J ∼ 7.8 Hz), 7.10 (1H, br d, J ∼ 7.8 Hz), 6.98 (1H, br t, 
J ∼ 7.8 Hz), 6.81 (1H, d, J = 16 Hz), 6.18 (1H, dt, J = 16, 7 Hz), 
5.23 (2H, s), 3.52 (3H, s), 3.49 (2H, t, J = 7 Hz), 2.42 (2H, br q, J 
∼ 7 Hz), 2.07 (2H, br quint, J ∼ 7 Hz); 13C NMR (125 MHz) δ 
154.1, 127.4 (C), 129.2, 128.1, 126.4, 125.8, 122.0, 115.0 (CH), 
94.8, 33.2, 32.4, 31.7 (CH2), 56.1 (CH3); HR EIMS m/z (rel. int.) 
284.0428 (M+, 60), 239 (M+−CH2OMe, 100). Calcd. for 
C13H1779BrO2, 284.0412. 
3j: oil; 1H NMR (500 MHz) δ 7.23 (1H, t, J = 7.8 Hz), 7.05 (1H, 
br t, J ∼ 2 Hz), 7.01 (1H, br d, J ∼ 7.8 Hz), 6.92 (1H, br dd, J ∼ 
7.8, 2.2 Hz), 6.43 (1H, d, J = 15.8 Hz), 6.18 (1H, dt, J = 15.8, 6.8 
Hz), 5.20 (2H, s), 3.50 (3H, s), 3.47 (2H, t, J = 6.8 Hz), 2.39 (2H, 
br q, J ∼ 6.8 Hz), 2.05 (2H, br quint, J ∼ 6.8 Hz); 13C NMR (125 
MHz) δ 157.5, 139.0 (C), 131.1, 129.5, 128.9, 119.8, 115.1, 
113.7 (CH), 94.4, 33.0, 32.2, 31.2 (CH2), 55.9 (CH3); HR EIMS 
m/z (rel. int.) 284.0416 (M+, 100), 254 (M+−CH2O, 36), 175 
(M+−CH2O −Br, 65). Calcd. for C13H1779BrO2, 284.0412. 
3k: oil; 1H NMR (500 MHz) δ 7.29 (2H, br d, J ∼ 8.5 Hz), 6.99 
(2H, br d, J ∼ 8.5 Hz), 6.41 (1H, d, J = 15.9 Hz), 6.05 (1H, dt, J = 
15.9, 6.8 Hz), 5.18 (2H, s), 3.49 (3H, s), 3.46 (2H, t, J = 6.8 Hz), 
2.37 (2H, br q, J ∼ 6.8 Hz), 2.04 (2H, br quint, J ∼ 6.8 Hz); 13C 
NMR (125 MHz) δ 156.5, 131.5 (C), 130.6, 127.1 (x 2), 126.8, 
116.3 (x 2) (CH), 94.5, 33.1, 32.3, 31.2 (CH2), 55.9 (CH3); HR 
EIMS m/z (rel. int.) 284.0353 (M+, 85), 254 (M+−CH2O, 76), 147 
(C5H8Br+, 100). Calcd. for C13H1779BrO2, 284.0412. 
 
6.2.3. Synthesis of combretastatin A-4 derivatives 2a-2n 
Representative example: A solution of 1a (63 mg, 0.2 mmol) 
in dry DMF (3 mL) was treated under N2 in the dark at room 
temperature with K2CO3 (70 mg, ca. 0.5 mmol) and stirred for 1 
h. Subsequently, 3a (52 µL, 0.6 mmol) was added and the stirring 
was continued for 24 h under the same conditions. The reaction 
mixture was then poured into saturated aqueous NH4Cl and 
extracted three times with Et2O (3 x 15 mL). The organic layer 
was dried over anhydrous Na2SO4, filtered and evaporated under 
reduced pressure. Column chromatography of the residue on 
silica gel (elution with hexane-EtOAc, 9:1) provided 2a (50 mg, 
70%). In the other cases, yields were in the range 40-70%. 
Bromides 3l-3n were used in excess as the mixtures with the 
homodimerization products (see above). Caution: reaction, 
work-up and purification procedures should be performed under 
minimization of exposure to light, due to the ease of 
photoinduced Z/E isomerization in the combretastatin moiety. 
2a: solid, mp 107-108 °C; 1H NMR (500 MHz) δ 6.86 (1H, dd, J 
= 8.3, 1.7 Hz), 6.84 (1H, d, J = 1.7 Hz), 6.79 (1H, d, J = 8.3 Hz), 
6.52 (2H, s), 6.50 (1H, d, J = 12.2 Hz), 6.46 (1H, d, J = 12.2 Hz), 
5.95 (1H, ddt. J = 17.2, 11.4, 5.5 Hz), 5.27 (1H, dq, J = 17.2, 1.5 
Hz), 5.20 (1H, dq, J = 11.4, 1.5 Hz), 4.40 (2H, dt, J = 5.5, 1.5 
Hz), 3.86 (3H, s), 3.84 (3H, s), 3.71 (6H, s); 13C NMR (125 
MHz) δ 153.0 (x 2), 148.7, 147.5, 137.2, 133.0, 129.8 (C), 133.1, 
129.7, 128.8, 122.3, 113.9, 111.3, 106.0 (x 2) (CH), 117.9, 69.7 
(CH2), 60.9, 56.0 (x 3) (CH3); HR ESMS m/z 379.1518 (M+Na+). 
Calcd. for C21H24NaO5, 379.1521. 
2b: oil; 1H NMR (500 MHz) δ 6.86 (2H, m), 6.74 (1H, d, J = 8.5 
Hz), 6.53 (2H, s), 6.50 (1H, d, J = 12.1 Hz), 6.44 (1H, d, J = 12.1 
Hz), 5.75-5.60 (2H, m), 4.30 (2H, br d, J ∼ 5.8 Hz), 3.85 (3H, s), 
3.84 (3H, s), 3.72 (6H, s), 1.70 (3H, br dd, J ∼ 6.5, 1.5 Hz); 13C 
NMR (125 MHz) δ 153.0 (x 2), 148.7, 147.6, 137.2, 133.0, 129.8 
(C), 130.8, 129.7, 128.7, 125.9, 122.0, 113.6, 111.1, 106.0 (x 2) 
(CH), 69.5 (CH2), 60.9, 56.0 (x 3), 17.7 (CH3); HR ESMS m/z 
393.1677 (M+Na+). Calcd. for C22H26NaO5, 393.1678. 
2c: solid, mp 83-84 °C; 1H NMR (500 MHz) δ 7.35-7.25 (5H, br 
m), 6.90-6.85 (2H, m), 6.80 (1H, d, J = 8.3 Hz), 6.51 (2H, s), 
6.47 (1H, d, J = 12.2 Hz), 6.43 (1H, d, J = 12.2 Hz), 4.94 (2H, s), 
3.87 (3H, s), 3.85 (3H, s), 3.71 (6H, s); 13C NMR (125 MHz) δ 
153.0 (x 2), 148.9, 147.7, 137.2, 136.9, 133.0, 129.8 (C), 133.1, 
129.6, 128.4 (x 2), 127.7, 127.2 (x 2), 122.4, 114.5, 111.5, 106.0 
(x 2) (CH), 70.9 (CH2), 60.9, 56.0, 55.9 (x 2) (CH3); HR ESMS 
m/z 429.1674 (M+Na+). Calcd. for C25H26NaO5, 429.1678. 
2d: solid, mp 62-63 °C; 1H NMR (500 MHz) δ 7.24 (2H, br d, J 
∼ 8.7 Hz), 6.95-6.85 (3H, m), 6.78 (2H, br d, J = 8.7 Hz), 6.52 
(2H, s), 6.47 (1H, d, J = 12.2 Hz), 6.43 (1H, d, J = 12.2 Hz), 4.87 
(2H, s), 3.85 (3H, s), 3.84 (3H, s), 3.81 (3H, s), 3.71 (6H, s); 13C 
NMR (125 MHz) δ 159.4, 153.0 (x 2), 149.0, 147.8, 137.2, 
133.0, 129.9, 129.1 (C), 129.7, 129.0 (x 2), 128.8, 122.4, 114.7, 
113.9 (x 2), 111.5, 106.0 (x 2) (CH), 70.7 (CH2), 60.9, 55.9 (x 3), 
55.3 (CH3); HR ESMS m/z 459.1783 (M+Na+). Calcd. for 
C26H28NaO6, 459.1784. 
2e: oil; 1H NMR (500 MHz) δ 7.44 (2H, br d, J ∼ 8.4 Hz), 7.18 
(2H, br d, J = 8.4 Hz), 6.88 (1H, dd, J = 8.3, 1.7 Hz), 6.83 (1H, d, 
J = 1.7 Hz), 6.80 (1H, d, J = 8.3 Hz), 6.50 (2H, s), 6.44 (2H, s), 
4.87 (2H, s), 3.86 (3H, s), 3.85 (3H, s), 3.71 (6H, s); 13C NMR 
(125 MHz) δ 153.0 (x 2), 149.0, 147.4, 137.2, 136.0, 133.0, 
129.8, 121.6 (C), 131.5 (x 2), 129.5, 128.8, 128.7 (x 2), 122.8, 
114.6, 111.5, 106.0 (x 2) (CH), 70.2 (CH2), 60.9, 56.0 (x 3) 
(CH3); HR ESMS m/z 507.0782 (M+Na+). Calcd. for 
C25H2579BrNaO5, 507.0783. 
2f: oil; 1H NMR (500 MHz) δ 7.41 (1H, dd, J = 7.7, 1.5 Hz), 7.19 
(1H, td, J = 7.7, 1.5 Hz), 6.91 (1H, td, J = 7.7, 1 Hz), 6.90-6.85 
(3H, m), 6.78 (1H, d, J = 8 Hz), 6.74 (1H, br d, J ∼ 15.8 Hz), 
6.53 (2H, s), 6.50 (1H, d, J = 12.2 Hz), 6.45 (1H, d, J = 12.2 Hz), 
6.22 (1H, dt, J = 15.8, 6.8 Hz), 3.90 (2H, t, J = 6.8 Hz), 3.86 (3H, 
s), 3.84 (6H, s), 3.70 (6H, s), 2.36 (2H, br q, J ∼ 7 Hz), 1.94 (2H, 
br quint, J ∼ 7 Hz); 13C NMR (125 MHz) δ 156.3, 153.0 (x 2), 
148.8, 148.1, 137.2, 133.0, 130.0, 126.8 (C), 130.4, 129.8, 128.8, 
127.9, 126.5, 125.2, 122.0, 120.7, 113.9, 111.5, 110.8, 106.0 (x 
2) (CH), 68.4, 29.8, 28.8 (CH2), 60.9, 56.1, 56.0 (x 2), 55.5 
(CH3); HR ESMS m/z 513.2247 (M+Na+). Calcd. for 
C30H34NaO6, 513.2253. 
2g: oil; 1H NMR (500 MHz) δ 7.21 (1H, t, J = 7.9 Hz), 6.94 (1H, 
br d, J ∼ 7.7 Hz), 6.90-6.85 (3H, m), 6.78 (1H, d, J = 8.6 Hz), 
6.76 (1H, dd, J = 8.3, 2.5 Hz), 6.53 (2H, s), 6.50 (1H, d, J = 12 
Hz), 6.45 (1H, d, J = 12 Hz), 6.38 (1H, br d, J ∼ 15.8 Hz), 6.23 
(1H, dt, J = 15.8, 6.8 Hz), 3.88 (2H, t, J = 6.7 Hz), 3.86 (3H, s), 
3.84 (3H, s), 3.82 (3H, s), 3.70 (6H, s), 2.34 (2H, br q, J ∼ 7 Hz), 
1.92 (2H, br quint, J ∼ 7 Hz); 13C NMR (125 MHz) δ 160.0, 
153.0 (x 2), 148.8, 148.0, 139.2, 137.2, 133.0, 130.0 (C), 130.4, 
130.1, 129.7, 129.4, 128.8, 122.1, 118.7, 113.8, 112.5, 111.5 (x 
2), 106.0 (x 2) (CH), 68.2, 29.4, 28.7 (CH2), 60.9, 56.0 (x 3), 55.2 
(CH3); HR ESMS m/z 513.2255 (M+Na+). Calcd. for 
C30H34NaO6, 513.2253. 
2h: oil; 1H NMR (500 MHz) δ 7.28 (2H, br d, J ∼ 8.5 Hz), 6.90-
6.85 (4H, m), 6.79 (1H, d, J = 8.2 Hz), 6.54 (2H, s), 6.50 (1H, d, 
J = 12 Hz), 6.46 (1H, d, J = 12 Hz), 6.36 (1H, br d, J ∼ 15.8 Hz), 
6.09 (1H, dt, J = 15.8, 6.8 Hz), 3.89 (2H, t, J = 6.7 Hz), 3.86 (3H, 
s), 3.85 (3H, s), 3.82 (3H, s), 3.71 (6H, s), 2.33 (2H, br q, J ∼ 7 
Hz), 1.92 (2H, br quint, J ∼ 7 Hz); 13C NMR (125 MHz) δ 158.7, 
153.0 (x 2), 148.8, 148.0, 137.2, 133.0, 130.6, 130.0 (C), 129.8, 
129.7, 128.7, 127.5, 127.1 (x 2), 122.0, 113.9 (x 2), 113.7, 111.4, 
106.0 (x 2) (CH), 68.2, 29.4, 28.8 (CH2), 60.9, 56.0 (x 3), 55.2 
(CH3); HR ESMS m/z 513.2256 (M+Na+). Calcd. for 
C30H34NaO6, 513.2253. 
2i: oil; 1H NMR (500 MHz) δ 7.44 (1H, dd, J = 7.9, 1.8 Hz), 7.16 
(1H, td, J = 7.9, 1.8 Hz), 7.07 (1H, dd, J = 8, 1 Hz), 6.97 (1H, td, 
J = 7.6, 1 Hz), 6.90-6.85 (2H, m), 6.78 (1H, d, J = 8 Hz), 6.75 
(1H, br d, J ∼ 15.8 Hz), 6.53 (2H, s), 6.50 (1H, d, J = 12 Hz), 
6.45 (1H, d, J = 12 Hz), 6.22 (1H, dt, J = 15.8, 6.8 Hz), 5.20 (2H, 
s), 3.90 (2H, t, J = 6.8 Hz), 3.86 (3H, s), 3.84 (3H, s), 3.70 (6H, 
s), 3.48 (3H, s), 2.38 (2H, br q, J ∼ 7 Hz), 1.94 (2H, br quint, J ∼ 
7 Hz); 13C NMR (125 MHz) δ 154.0, 153.0 (x 2), 148.8, 148.1, 
137.2, 133.0, 130.0, 127.7 (C), 130.5, 129.8, 128.8, 127.9, 126.4, 
125.0, 122.0, 121.9, 114.9, 113.8, 111.5, 106.0 (x 2) (CH), 94.8, 
68.3, 29.8, 28.8 (CH2), 60.9, 56.1, 56.0, 55.9 (x 2) (CH3); HR 
ESMS m/z 543.2362 (M+Na+). Calcd. for C31H36NaO7, 543.2359. 
2j: oil; 1H NMR (500 MHz) δ 7.21 (1H, t, J = 7.8 Hz), 7.02 (1H, 
br s), 7.00 (1H, br d, J ∼ 8 Hz), 6.90-6.85 (3H, m), 6.78 (1H, d, J 
= 8.4 Hz), 6.54 (2H, s), 6.50 (1H, d, J = 12 Hz), 6.46 (1H, d, J = 
12 Hz), 6.38 (1H, br d, J ∼ 15.7 Hz), 6.23 (1H, dt, J = 15.7, 6.8 
Hz), 5.19 (2H, s), 3.88 (2H, t, J = 6.6 Hz), 3.86 (3H, s), 3.84 (3H, 
s), 3.70 (6H, s), 3.49 (3H, s), 2.34 (2H, br q, J ∼ 7 Hz), 1.91 (2H, 
br quint, J ∼ 7 Hz); 13C NMR (125 MHz) δ 157.5, 153.0 (x 2), 
148.8, 148.0, 139.2, 137.2, 133.0, 129.9 (C), 130.3, 130.2, 129.7, 
129.4, 128.8, 122.0, 119.8, 114.8, 113.8, 113.7, 111.4, 106.0 (x 
2) (CH), 94.4, 68.2, 29.4, 28.7 (CH2), 60.8, 55.9 (x 4) (CH3); HR 
ESMS m/z 543.2359 (M+Na+). Calcd. for C31H36NaO7, 543.2359. 
2k: oil; 1H NMR (500 MHz) δ 7.26 (2H, br d, J ∼ 8.5 Hz), 6.97 
(2H, br d, J ∼ 8.5 Hz), 6.90-6.85 (2H, m), 6.78 (1H, d, J = 8.2 
Hz), 6.53 (2H, s), 6.50 (1H, d, J = 12.3 Hz), 6.45 (1H, d, J = 12.3 
Hz), 6.36 (1H, br d, J ∼ 15.7 Hz), 6.10 (1H, dt, J = 15.7, 6.8 Hz), 
5.17 (2H, s), 3.88 (2H, t, J = 6.8 Hz), 3.86 (3H, s), 3.84 (3H, s), 
3.70 (6H, s), 3.48 (3H, s), 2.32 (2H, br q, J ∼ 7 Hz), 1.91 (2H, br 
quint, J ∼ 7 Hz); 13C NMR (125 MHz) δ 156.4, 153.0 (x 2), 
148.8, 148.0, 137.2, 133.0, 131.8, 130.0 (C), 129.8, 129.7, 128.8, 
128.1, 127.1 (x 2), 122.0, 116.3 (x 2), 113.8, 111.4, 106.0 (x 2) 
(CH), 94.5, 68.3, 29.4, 28.8 (CH2), 60.9, 56.0 (x 4) (CH3); HR 
ESMS m/z 543.2360 (M+Na+). Calcd. for C31H36NaO7, 543.2359. 
2l: oil; 1H NMR (500 MHz) δ 7.30 (2H, m), 6.98 (2H, m), 6.90-
6.85 (2H, m), 6.79 (1H, d, J = 8.3 Hz), 6.53 (2H, s), 6.50 (1H, d, 
J = 12.1 Hz), 6.45 (1H, d, J = 12.1 Hz), 6.37 (1H, br d, J ∼ 15.8 
Hz), 6.14 (1H, dt, J = 15.8, 6.8 Hz), 3.88 (2H, t, J = 6.8 Hz), 3.86 
(3H, s), 3.84 (3H, s), 3.70 (6H, s), 2.33 (2H, br q, J ∼ 7 Hz), 1.91 
(2H, br quint, J ∼ 7 Hz); 13C NMR (125 MHz) δ 162.9/161.0 [d, 
1JC−F ~ 244 Hz], 153.0 (x 2), 148.8, 148.0, 137.2, ∼133.9 [d, 4JC−F 
~ 3 Hz], 133.0, 129.9 (C), 129.7, 129.5, 129.3, 128.8, ∼127.4 [d, 
3JC−F ~ 8 Hz] (x 2), 122.1, 115.3/115.2 [d, 2JC−F ~ 21 Hz], (x 2), 
113.7, 111.4, 106.0 (x 2) (CH), 68.2, 29.3, 28.7 (CH2), 60.9, 56.1, 
56.0 (x 2) (CH3); HR ESMS m/z 501.2052 (M+Na+). Calcd. for 
C29H31FNaO5, 501.2053. 
2m: oil; 1H NMR (500 MHz) δ 7.26 (4H, br s), 6.88 (1H, dd, J = 
8.2, 1.7 Hz), 6.85 (1H, d, J = 1.7 Hz), 6.79 (1H, d, J = 8.2 Hz), 
6.53 (2H, s), 6.50 (1H, d, J = 12 Hz), 6.45 (1H, d, J = 12 Hz), 
6.36 (1H, br d, J ∼ 15.8 Hz), 6.21 (1H, dt, J = 15.8, 6.8 Hz), 3.87 
(2H, t, J = 6.8 Hz), 3.85 (3H, s), 3.84 (3H, s), 3.70 (6H, s), 2.34 
(2H, br q, J ∼ 7 Hz), 1.91 (2H, br quint, J ∼ 7 Hz); 13C NMR (125 
MHz) δ 153.0 (x 2), 148.8, 147.9, 137.2, 136.2, 133.0, 132.5, 
129.9 (C), 130.5, 129.7, 129.3, 128.8, 128.5 (x 2), 127.2 (x 2), 
122.1, 113.7, 111.4, 106.0 (x 2) (CH), 68.2, 29.4, 28.6 (CH2), 
60.9, 56.0 (x 3) (CH3); HR ESMS m/z 517.1761 (M+Na+). Calcd. 
for C29H3135ClNaO5, 517.1758. 
2n: oil; 1H NMR (500 MHz) δ 7.41 (2H, br d, J = 8.5 Hz), 7.20 
(2H, br d, J = 8.5 Hz), 6.87 (1H, dd, J = 8.2, 1.8 Hz), 6.85 (1H, d, 
J = 1.8 Hz), 6.79 (1H, d, J = 8.2 Hz), 6.53 (2H, s), 6.50 (1H, d, J 
= 12 Hz), 6.45 (1H, d, J = 12 Hz), 6.35 (1H, br d, J ∼ 15.8 Hz), 
6.22 (1H, dt, J = 15.8, 6.8 Hz), 3.87 (2H, t, J = 6.8 Hz), 3.85 (3H, 
s), 3.84 (3H, s), 3.70 (6H, s), 2.33 (2H, br q, J ∼ 7 Hz), 1.90 (2H, 
br quint, J ∼ 7 Hz); 13C NMR (125 MHz) δ 153.0 (x 2), 148.8, 
147.9, 137.2, 136.6, 133.0, 131.5, 129.9 (C), 131.4 (x 2), 130.7, 
129.7, 129.4, 128.8, 127.5 (x 2), 122.1, 113.7, 111.4, 106.0 (x 2) 
(CH), 68.2, 29.4, 28.6 (CH2), 60.9, 56.1, 56.0 (x 2) (CH3); HR 
ESMS m/z 561.1248 (M+Na+). Calcd. for C29H3179BrNaO5, 
561.1253. 
 
6.3. Biological procedures 
6.3.1. Reagents and cell culture 
Cell culture media were purchased from Gibco (Grand Island, 
NY, USA) and Biowhittaker (Walkersville, MD, USA). Fetal 
bovine serum (FBS) was a product of Harlan-Seralab (Belton, 
U.K.). Matrigel was purchased from Becton Dickinson (Bedford, 
MA, USA). Supplements and other chemicals not listed in this 
section were obtained from Sigma Chemicals Co. (St. Louis, 
Mo., USA). Plastics for cell culture were supplied by NUNC 
(Roskilde, Denmark). Combretastatin derivatives 2a-n (samples 
purified by HPLC) were dissolved in DMSO at a concentration 
of 10 mg/mL and stored at –20°C until use. 
Cell lines were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) containing glucose (1 g/L), glutamine (2 mM), 
penicillin (50 IU/mL), streptomycin (50 µg/mL) and 
amphoterycin (1.25 µg/mL), supplemented with 10% FBS. 
6.3.2. Cell proliferation assay 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT; Sigma Chemical Co., St. Louis, MO) dye 
reduction assay in 96-well microplates was used, as previously 
described.34 Some 5 x 103 cells of HT-29, MCF-7 or HEK-293 
cells in a total volume of 100 µL of their respective growth media 
were incubated with serial dilutions of the tested compounds. 
After 3 days of incubation (37 oC, 5% CO2 in a humid 
atmosphere), 10 µl of MTT (5 mg/ml in PBS) were added to each 
well and the plate was incubated for further 4 h (37 oC). The 
resulting formazan was dissolved in 150 µL of 0.04 N HCl/2-
propanol and read at 550 nm. All determinations were carried out 
in triplicate. The IC50 values in Table 1 mean the concentration of 
compound yielding a 50% of cell survival. 
6.3.3. RT-PCR analysis 
HT-29 cells at 70–80% confluence were collected after serum 
starvation for 24 h. Cells were incubated with combretastatin 
derivatives in DMSO (see Figs. 4 and 5) for 48 h. Cells were 
collected and the total cellular RNA from HT-29 cells was 
isolated using Ambion RNA extraction Kit according to the 
manufacturer’s instructions. The cDNA was synthesized by 
MMLV-RT with 1-21 µg of extracted RNA and oligo(dT)15 
according to the manufacturer’s instructions. Gene-specific PCR 
primers (see Table 3) were then added for amplification. PCR 
products were analysed by electrophoresis on 1.5% agarose gels 
and visualized by ethidium bromide staining under UV 
transillumination. The sequences of primers used in the RT-PCR 
are listed in Table 3. The PCR conditions were as follows: VEGF 
at 94 ºC for 30 s, at 58 ºC for 1 min, and at 72 ºC for 1 min 50 s; 
and β-actin at 94ºC for 30 s, at 58 ºC for 50 s, and at 72 ºC for 50 
s; hTERT: 94 ºC for 1 min, 57 ºC for 1 min and 72 ºC for 1 min 
30 s; c-Myc: 94 ºC for 30 s, 58 ºC for 1 min, and 72 ºC for 1 min 
50 s. 
Analysis of β-actin was used to monitor RNA integrity and 
accuracy of loading.35 
 
Table 3. Primers used and sizes of the PCR products. 
VEGF Sense: 5’-CCTGATGAGATCGAGTACATCTT-3’ 
Antisense: 5’-ACCGCCTCGGCTTGTCAC-3’ 
379 
hTERT Sense: 5’-CGGAAGAGTGTCTGGAGCAA-3’ 
Antisense: 5’-GGATGAAGCGGAGTCTGGA-3’ 
145 
c-Myc Sense: 5’-AAGTCCTGCGCCTCGCAA-3’ 249 
Antisense: 5’-GCTGTGGCCTCCAGCAGA-3’ 
β-Actin Sense: 5’-TCATGAAGTGTGACGTTGACATC 
CGT-3’ 
Antisense: 5’-CGTAGAAGCATTTGCGGTGCAC 
GATG-3’ 
287 
 
6.3.4. ELISA analysis 
HT-29 cells at 70–80% confluence were collected after serum 
starvation for 24 h. Cells were incubated with combretastatin 
derivatives in DMSO (see Fig. 3) for 72 h. Culture supernatants 
were collected and VEGF secreted by HT-29 cells was 
determined using Invitrogen Human Vascular Endothelial 
Growth Factor ELISA Kit according to the manufacturer’s 
instructions. 
 
Supplementary Data 
Supplementary data associated with this paper (graphical 
NMR spectra of compounds 2a-2n) can be found in the online 
version. 
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